Forest/Almirall’s Aclidinium Disappoints In Phase III COPD Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Bronchodilatory effect of aclidinium was statistically significant compared to placebo, but lower than seen in previous studies.